Five Prime founder Rusty Williams sets out to test the limits of cell therapy with axolotl-inspired biotech
Eighteen years after launching Five Prime Therapeutics, serial entrepreneur Lewis “Rusty” Williams was itching to start something new again. So he assembled the “best of the best” of his old colleagues at a bar and grill near Five Prime’s headquarters and got to work on biopharma’s latest puzzle: using B cells to break the boundaries of cell therapy.
A couple years later, the group has upgraded their corner table to office space in the Bay Area — and on Monday, the company they founded, Walking Fish, unveiled a $50 million Series A round to fund a push toward the clinic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.